央视网消息：据市场监管总局网站消息，为充分发挥典型案例的示范引领作用，助力经营主体合规发 展，市场监管总局在现有的经营者集中简易案件公示、附条件批准案件和禁止案件审查决定公告、无条 件批准案件列表公示等案件公开制度的基础上，进一步加大经营者集中审查案件公开力度，现选取3起 无条件批准的非简易案件典型案例予以公布。 本次公布的典型案例涉及不同交易类型与行业，如涉及工业气体领域横向集中的杭州市国有资本投资运 营有限公司收购浙江盈德控股集团有限公司股权案、涉及药品零售领域纵向集中的高济医药有限公司收 购天济大药房连锁有限公司等三家公司股权案等。公开这些典型案例有利于帮助企业进一步提高申报效 率和申报质量，为投资并购营造公开、透明、可预期的制度环境。 相关案例不是案件事实的完整复现，重点在于呈现反垄断执法机构在经营者集中审查实践中的关注要点 与竞争分析思路，包括案件程序的适用，控制权变化的认定，相关市场的界定，横向、纵向等关系的认 定，市场份额和市场集中度的估算，评估单边效应、协调效应、封锁效应的考虑因素，相关证据材料的 考量等，在参考使用上需要结合具体情境灵活运用。 典型案例1 杭州市国有资本投资运营有限公司收购浙 ...

Group 1 - Recently, China Resources (Xinxiang) Pharmaceutical Co., Ltd. was established with a registered capital of 30 million yuan [1] - The company's business scope includes pharmaceutical wholesale and food sales [1] - The company is wholly owned by China Resources Henan Pharmaceutical Co., Ltd. [1]

Group 1 - Hunan Pharmaceutical Group Traditional Chinese Medicine Materials Co., Ltd. has been established with a registered capital of 25 million RMB [1] - The legal representative of the new company is Shen Zhihua [1] - The company's business scope includes pharmaceutical wholesale, traditional Chinese medicine decoction services, and agricultural product quality safety testing [1] Group 2 - The company is wholly owned by Hunan Pharmaceutical Group Co., Ltd. [1]

Group 1 - The core point of the article is the revised articles of association of Guangxi Liuyao Group Co., Ltd. which aim to protect the rights and interests of the company, shareholders, employees, and creditors while regulating the company's organization and behavior [1][2][3] - The company was established as a joint-stock company in accordance with the Company Law and other relevant regulations, with a registered capital of RMB 397,168,905 [2][3] - The company is committed to the health industry, providing professional pharmaceutical distribution services, and aims to become an innovative enterprise in the pharmaceutical circulation field [5][6] Group 2 - The company’s business scope includes wholesale and retail of pharmaceuticals, medical device operations, and various related services [5][6] - The company has issued a total of 397,168,905 shares, all of which are ordinary shares with a par value of RMB 1 per share [7][8] - The company can increase its capital through various methods, including issuing shares to unspecified objects or existing shareholders [10][11] Group 3 - The company’s shareholders have rights to dividends, participate in shareholder meetings, and supervise the company's operations [15][16] - The company must hold an annual general meeting within six months after the end of the previous fiscal year [50][51] - The company’s articles stipulate that any significant transactions must be approved by the board and submitted to the shareholders' meeting for approval [24][26]

Core Viewpoint - Dajia Weikang's stock price experienced a slight decline on August 25, closing at 12.61 yuan, down 0.06 yuan or 0.47% from the previous trading day [1] Company Overview - Dajia Weikang is a pharmaceutical commercial enterprise involved in drug wholesale, retail, and logistics distribution services [1] - The company utilizes an intelligent logistics center that integrates "intelligent warehousing hardware + digital systems" technology for comprehensive management of drug circulation [1] Business Development - The company has indicated on its investor interaction platform that its business segments have not yet integrated with AI models like DeepSeek or ChatGPT, but it is actively pursuing collaborations with AI companies, universities, and research institutions to explore the integration of new technologies with existing operations [1] Market Activity - On August 25, the net outflow of main funds was 17.18 million yuan, accounting for 0.99% of the circulating market value [1] - Over the past five trading days, the cumulative net outflow reached 34.00 million yuan, representing 1.96% of the circulating market value [1]

Core Viewpoint - Recently, Shanghai Pharmaceuticals (601607) established a new subsidiary, Up Pharmaceutical Holdings (Yongzhou) Co., Ltd., with a registered capital of 20 million yuan, indicating an expansion in its operational capabilities in the pharmaceutical sector [1] Company Summary - The new company is co-owned by Shanghai Pharmaceuticals' subsidiary, Up Pharmaceutical Holdings (Hunan) Co., Ltd., and Yongzhou Big Health Industry Co., Ltd., reflecting a strategic partnership in the health industry [1] - The business scope of the new entity includes drug wholesale, sales of Class II and III radiation devices, operation of Class III medical devices, general equipment repair, and professional design services, showcasing a diverse range of services [1]

Group 1 - The stock price of the company is reported at 8.34 yuan, down 0.04 yuan from the previous trading day, with a trading volume of 101,500 hands and a transaction amount of 85 million yuan [1] - The company's main business is in pharmaceutical commerce, covering drug wholesale and retail [1] - In the first half of 2025, the company achieved operating revenue of 5.149 billion yuan, a year-on-year increase of 3.29%, but the net profit attributable to shareholders decreased by 46.31% to 72.5792 million yuan [1] Group 2 - The decline in performance is primarily attributed to the impact of centralized procurement policies, which have pressured the gross profit margin of the wholesale business [1] - The company reported a significant increase in credit impairment losses, reaching 33.8926 million yuan in the first half of the year, with a year-on-year increase of 43.8% in the provision for bad debts on accounts receivable [1] - The latest announcement indicates that the bad debt provision ratio for accounts receivable aged 2-3 years is as high as 83.11% [1]